Efficacy of Cardiac Resynchronization Therapy Using Automated Dynamic Optimization and Left Ventricular-only Pacing.
CONCLUSION: In our first Asian-Pacific real-world data, automated dynamic CRT optimization showed comparable efficacy to conventional methods regarding clinical outcomes and electromechanical remodeling. PMID: 31293111 [PubMed - in process]
The Food and Drug Administration approved AstraZeneca's drug Farxiga as a treatment for reducing the risk of hospitalizations for heart failure in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Farxiga, developed by AstraZeneca (NYSE: AZN) in a partnership with Bristol-Myers Squibb, already had FDA approval as a therapy along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug generated sales of more than…
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
ConclusionsIn this observational analysis of T2D and ASCVD, baseline beta-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic beta-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
ConclusionsOur results suggest that sex-specific differences in LV geometry, hyper-contractility and diastolic function, not greater degree of LV myopathy, contribute to a higher, age-independent risk of diastolic HF in women with HCM.Graphical abstract
Dapagliflozin (Farxiga, AstraZeneca) has additionally been approved in the US for reducing hospitalization for heart failure (HF) in adults with type 2 diabetes and other cardiovascular risk factors.FDA Approvals
Conditions: Sleep Disorder; Breathing-Related; Heart Failure Intervention: Behavioral: Active Patient Engagement Sponsors: Thomas Jefferson University; Inova Fairfax Hospital; Heart and Diabetes Center North Rhine-Westphalia; CLEMENS HOSPITAL; Resmed Inc Recruiting
CONCLUSION AND RECOMMENDATION: Even if more than half of study respondents have, good medication and self-care adherence still it need great attention in health education over on their visit. We recommend health institution strongly to give health education for clients and researcher to use advanced study design for measuring medication adherence and self-care behaviors. PMID: 31629399 [PubMed - as supplied by publisher]
ConclusionType D personality was not significantly associated with increased risk of all-cause mortality or cardiovascular death in patients with non-ischemic HF.
At present, there are no unanimous criteria of surgical indications for Takayasu arteritis (TA) patients, although ischemic symptoms of organs or limbs and aneurysms at risk of rupture may be widely in consensus. However, because heart failure has been proved to be a leading cause of death in TA patients, abnormal hemodynamics should also be considered a surgical indication to ease the burden on the heart and to improve patients ’ prognoses.
AstraZeneca's diabetes drug Farxiga has been approved for use in the United States as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks, the British drugmaker said on Monday.